BFM
OMED

Boothbay Fund Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Boothbay Fund Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-38,432
Closed -$122K – 1005
2018
Q1 		$122K Buy
+38,432
New +$106K 0.01% 635

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Boothbay Fund Management's OMED Position: Q2 2018 in Review

Boothbay Fund Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 38,432 shares — an estimated $122K sold.

Boothbay Fund Management first reported a position in OMED in Q1 2018 and held it in 1 quarter. The position peaked at $122K in Q1 2018. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

  • Boothbay Fund Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Boothbay Fund Management sold 38,432 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $122K.
  • Boothbay Fund Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Boothbay Fund Management's OncoMed Pharmaceuticals, Inc. position peaked at $122K in Q1 2018.
  • 63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on Boothbay Fund Management's 13F filing for Q2 2018, filed 14 Aug 2018.